Navacaprant [CAS 2244614-14-8]

Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC50 values of 0.8 nM, 110 nM, and 6500 nM, respectively. Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy[1].

[2244614-14-8]

C25H32FN5O2

453.56

CC1=NOC(C2=C(C)C3=CC(CC)=CC(F)=C3N=C2N4CCC(NC5CCOCC5)CC4)=N1

Opioid Receptor

δ Opioid Receptor/DOR; κ Opioid Receptor/KOR; μ Opioid Receptor/MOR

99.97

1 M HCl : 3.33 mg/mL (ultrasonic) |DMSO : 3.85 mg/mL (ultrasonic; warming; adjust pH to 4 with HCl; heat to 60°C)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H302, H315, H319

H302, H315, H319